Abstract:In recent years, research has highlighted radiotherapy's (RT) capacity to induce Immunogenic Cell Death (ICD), activating tumor-infiltrating Dendritic Cells (DCs) for cross-presenting tumor-associated antigens (TAAs), leading to robust systemic immune responses. Simultaneously, emerging studies underscore the gut microbiota's crucial role in modulating immunity across diverse human diseases. Our investigation focuses on gut microbiome modulation, specifically using oral Vancomycin, a locally acting antibiotic. This approach enhances the direct and abscopal antitumor effects of RT, evident across multiple cancer models. Findings demonstrate Vancomycin significantly increases CD8+ T cell infiltration, targeting TAAs in primary and abscopal tumors, leading to elevated IFN-β and IFN-γ expression in tumor-derived lymph nodes (TDLNs). Vancomycin's remarkable influence on RT effectiveness directly traces back to its impact on the gut microbiome composition, including a shift from gram-positive to gram-negative bacteria, enrichment of Vancomycin-resistant strains, reduced bacterial diversity, and decreased SCFA concentrations.. Building on these compelling outcomes, we initiated a randomized pilot study involving stage I non-small cell lung cancer (NSCLC) patients undergoing stereotactic body RT (SBRT). Patients were randomized to receive Vancomycin versus placebo, administered at 125 mg four times daily, commencing one week before SBRT and continuing during and after treatment for five total weeks. In an interim analysis, despite a small sample size, significant improvements in Progression-Free Survival (PFS) and Overall Survival (OS) were observed in those receiving the combination therapy. Additional investigations have reaffirmed our earlier findings in mice, emphasizing the depletion of specific bacterial populations, the rise in Vancomycin-resistant strains, and substantial reductions in SCFA concentrations in stool samples. Pathway analysis further underscores the impact of oral Vancomycin on gene expression related to the cross-presentation of TAAs. Together, these findings from both murine and human studies robustly affirm the concept that modulating the gut microbiome with Vancomycin can augment the ability of RT to trigger an anti-cancer immune response. We posit that this pioneering strategy is not only cost-effective but also holds the promise of substantially enhancing patient outcomes. Citation Format: Steven J. Feigenberg, Francesca Costabile, Stefano Pierini, Nektarios Kostopoulos, Renzo Perales-Linares, Mireia Uribe-Herranz, Edgar Ben-Josef, Costa Koumeis, Andrea Facciabene. Harnessing radiation and microbiome modulation for enhanced antitumor immune response in early-stage NSCLC treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6671.

ATP-dependent proteases in prokaryotic and eukaryotic cells.

Abscopal Effects Induced by Radiotherapy Combined with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Recurrent or Refractory Metastatic Thymic Epithelial Tumors: A Single-Institution Experience

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

Combining SBRT with GM-CSF and Peg-IFNα to Induce Abscopal Effects in Previously Treated Patients with Stage IV Thymic Tumors

Abscopal Effect and Safety of Recurrent and Refractory Advanced Malignant Thymoma or Thymic Carcinoma Treated with Combined Therapy of Local Radiotherapy and Granulocyte-macrophage Colony-stimulating Factor

Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.

A unique apudoma producing the glucagonoma and gastrinoma syndromes.

Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation

Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review

Effect of Low-Dose Radiotherapy on Abscopal Responses to Hypofractionated Radiotherapy and Anti-Pd1 in Mice and NSCLC Patients.

Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Abstract 6671: Harnessing radiation and microbiome modulation for enhanced antitumor immune response in early-stage NSCLC treatment

Using immunotherapy to boost the abscopal effect

Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer

Systemic Effects of Radiation Therapy-Induced Abscopal Responses in Patients with Advanced Lung Cancer

Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies

FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer.

The 2013 George W. Beadle Award

Nanotechnology-enhanced radiotherapy and the abscopal effect: Current status and challenges of nanomaterial-based radio-immunotherapy

Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity